Xoma Royalty (XOMA) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Xoma Royalty Corporation  (NASDAQ: XOMA)


Xoma Royalty's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Xoma Royalty's ROA in the first quarter of 2026?
Xoma Royalty Corporation achieved a return on average assets (ROA) of 7.73 % in its first quarter of 2026, this is above XOMA's average return on assets of -35.26%.
Xoma Royalty Corporation assets over the 12 months ending in its first quarter of 2026 are valued at $258 million

Despite the company's net income deteriorating, Xoma Royalty was able to improve its ROA compared to the fourth quarter of 2025.

However, within the Healthcare sector 120 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 800, from total ROA ranking in the fourth quarter of 2025 at 946.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Total Assets Change 27.86 % 23.24 % 17.98 % -8.13 % -3.1 %
Y / Y Net Income Change 200.85 % - - -45.99 % -
Net Income (TTM) in million 20 19 13 -15 -10
Return On Assets (TTM) 7.73 % 7.62 % 5.6 % -6.68 % -4.44 %
XOMA's Total Ranking # 800 # 946 # 1084 # 3129 # 3026
Total Assets (TTM) in million 272 273 263 223 213
Seq. Total Assets Change -0.31 % 3.63 % 17.76 % 5.1 % -3.91 %
Seq. Net Income Change -35.88 % -63.17 % 62.64 % 683.26 % -

XOMA's 5 Years Annual ROA >> Back to XOMA Management Effectiveness >> Compare XOMA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 46
Sector # 121
Overall # 794

Return On Assets Statistics
High Average Low
28.68 %
-35.26 %
-214.86 %
(Mar 31 2018)   (Mar 31 2017)



  News about Xoma Royalty Corporation Return on Assets ROA

XOMA Corporation Demonstrates Commitment to Shareholders and Receives $8.1 Million Milestone Payment Amidst Challenging Stock Performance

XOMA s Cash Infusion and Commitment to Shareholders Amidst Stock Performance Challenges
EMERYVILLE, Calif., June 12, 2024 - XOMA Corporation (NASDAQ: XOMA), a biotech royalty aggregator, recently received an $8.1 million milestone payment from Viracta Therapeutics, Inc., following the sale of Day One Biopharmaceuticals Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. This significant cash infusion comes at a crucial time for XOMA as the company has been grappling with a cumulative net loss of $-45 million over the past 12 months, resulting in a negative return on assets (ROA) of -25.64%.
Despite these financial challenges, XOMA Corporation remains optimistic about its future prospects. Within the healthcare sector, although 280 other companies have a higher return on assets, XOMA s ROA ranking has improved from 3327 in the fourth quarter of 2023 to 2667 in the first quarter of 2024. This improvement suggests that the company s efforts to turn its financial situation around might be yielding some positive results.



Financial Statements
Xoma Royalty's Assets $ 272 million XOMA's Balance sheet
Xoma Royalty's Income $ 2 million Quarterly XOMA's Income Statement
XOMA's Income by Division See XOMA's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 23.24 % -5.56 % 66.9 % -15.72 % 34.23 %
Total Assets in million 273 221 234 140 167
Y / Y Net Income Change - - - - -11.44 %
Net Income in million 19 -19 -46 -23 8
Annual Return On Assets 6.79 % -8.72 % -19.76 % -16.08 % 4.68 %

XOMA's 5 Years Annual ROA >> Back to XOMA Management Effectiveness >> Compare XOMA ROA to its Competitors



Comment on XOMA's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 6.79 % compared to prior year, due to annual net income growth of % to $18.52 million, while value of Xoma Royalty's overall assets grew just by 23.24 % to $272.70 million, compared to $272.70 a year before.


More Return On Assets Ratios
XOMA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
XOMA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for XOMA's Competitors
Subscribers only: Roa for Xoma Royalty's Suppliers
Subscribers only: Return On Assets for XOMA's Customers

You may also want to know
XOMA's Roi XOMA's Inventory Turnover Ratio XOMA's Growth Rates XOMA's Dividend Comparisons
XOMA's Profitability Ratios XOMA's Asset Turnover Ratio XOMA's Dividend Growth
XOMA's Roe XOMA's Valuation Ratios XOMA's Financial Strength Ratios XOMA's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA
Iradimed Corporation  21.25 %
Catalyst Pharmaceuticals Inc   20.71 %
Engene Therapeutics Inc   20.52 %
Vaxart Inc   20.07 %
Indivior Pharmaceuticals Inc   19.14 %
Pro dex Inc   18.35 %
Electromed Inc   18.31 %
Soleno Therapeutics Inc  18.25 %
Resmed Inc   18.18 %
Protalix Biotherapeutics inc   17.75 %
Krystal Biotech Inc   17.62 %
Zoetis Inc   17.60 %
United Therapeutics Corporation  17.25 %
Vertex Pharmaceuticals Inc  17.18 %
Chemed Corporation  16.20 %
Gilead Sciences Inc   16.06 %
Transmedics Group Inc   15.85 %
Inspire Medical Systems inc   15.30 %
Neurocrine Biosciences Inc   15.12 %
Strata Critical Medical Inc   15.09 %
Intuitive Surgical Inc   14.98 %
Halozyme Therapeutics Inc   14.73 %
Profound Medical Corp   13.91 %
Aveanna Healthcare Holdings Inc   13.73 %
Standard Biotools Inc   13.58 %
Illumina Inc   13.40 %
Dexcom Inc   13.39 %
West Pharmaceutical Services Inc   13.21 %
Apellis Pharmaceuticals Inc   13.20 %
Prestige Consumer Healthcare Inc   13.01 %

Date modified: 2026-09-18T13:11:06+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.